Sermorelin and CJC-1295 belong to the same family of synthetic growth-hormone-releasing hormone (GHRH) analogs, yet they differ markedly in how long they remain active. This note compares their structural modifications, the secretagogue mechanism they share, and the pharmacokinetic differences that separate a brief pulse from a multi-day plateau.

The GHRH-analog family

All members of this family are agonists of the GHRH receptor, a class B G-protein-coupled receptor on pituitary somatotrophs whose activation raises intracellular cAMP and stimulates growth-hormone release. The functional core of native GHRH resides in its first 29 residues, so analogs in this group are typically built on or around the GHRH(1-29) fragment and then engineered for stability or extended residence.

Sermorelin: GHRH(1-29)

Sermorelin is the GHRH(1-29) sequence, the shortest fragment that retains full receptor activity. It is essentially the unmodified active core, and as such it is rapidly cleared from plasma with a short half-life on the order of minutes. In research models this produces a sharp, transient stimulus to the GH axis that closely resembles a single physiological GHRH pulse.

CJC-1295 and the DAC modification

CJC-1295 builds on a modified GHRH(1-29) backbone and, in its drug-affinity-complex (DAC) form, adds a maleimidopropionyl linker that covalently binds circulating serum albumin. This albumin tethering shields the peptide from rapid clearance and proteolysis, extending its functional half-life from minutes to several days. A non-DAC variant lacks this linker and behaves more like the short-acting analogs.

Pulse versus plateau

The pharmacokinetic contrast is the practical distinction researchers draw between the two. Sermorelin's brief exposure drives a discrete pulse, whereas albumin-bound CJC-1295 maintains an extended plateau of receptor stimulation. Because the GH axis is normally pulsatile and feedback-regulated, the kinetic profile of an analog shapes how it interacts with that rhythm in experimental systems.

Secretagogue mechanism versus administering GH

A theme common to the whole family is that these analogs are secretagogues: they prompt the pituitary to release its own growth hormone rather than supplying the hormone exogenously. This preserves the upstream feedback architecture of the GH/IGF-1 axis, a mechanistic distinction frequently highlighted in the comparative literature on GHRH analogs.

These materials are for laboratory research use only and are not for human or veterinary use.